Hologic (NASDAQ:HOLX – Get Free Report) issued its quarterly earnings results on Monday. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04, Briefing.com reports. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the business posted $0.93 EPS. The company’s revenue for the quarter was up 2.7% on a year-over-year basis.
Hologic Price Performance
NASDAQ:HOLX opened at $79.64 on Tuesday. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52. The firm has a market cap of $18.59 billion, a PE ratio of 40.63, a price-to-earnings-growth ratio of 2.62 and a beta of 0.99. Hologic has a 12 month low of $64.02 and a 12 month high of $81.00. The company’s 50-day moving average price is $74.66 and its two-hundred day moving average price is $75.08.
Insider Transactions at Hologic
In other news, Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the transaction, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the transaction, the director now directly owns 45,472 shares of the company’s stock, valued at $3,615,024. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephen P. Macmillan sold 3,672 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on Hologic
About Hologic
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Read More
- Five stocks we like better than Hologic
- What is the NASDAQ Stock Exchange?
- Should You Invest in Bonds? Here’s What to Know
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Why This Manufacturer is Committing to a Massive Buyback Program
- Upcoming IPO Stock Lockup Period, Explained
- Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.